The patient with Alzheimer’s pathologic change that did not yet show evidence of tau pathology ([18F]PI-2620 PET) and who had no significant neurodegeneration as assessed by β-amyloid-PET perfusion imaging (A + T-N-), revealed high cortical and subcortical [18F]F-DED binding with regional predominance in cortical AD signature regions (Fig. 5; Additional file 1: Figs. S4–S7). This evidence concerns the gene MAPT and Alzheimer disease.